Oxcarbazepine (Epilepsy)

Cognitive developmental disorders/delay (< 3 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9934
R53726		 Videman (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2016 Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 1.32 [0.24;7.16]
excluded (control group) 		-/10   -/8 - 10
ref
S9941
R53727		 Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016 Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No extrapolated (cont. endpoint) 5.76 [1.65;20.16] -/10   -/59 - 10
ref
Total 1 studies 5.76 [1.65;20.13] 0 10
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Videman (Oxcarbazepine) (Controls unexposed, disease free), 2016Videman, 2016 1 5.76[1.65; 20.16]-100%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate0.920.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1 Tags Adjustment   - No  - No 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1 All studiesAll studies 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 10.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9934

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.76[1.65; 20.13]-10 -NAVideman (Oxcarbazepine) (Controls unexposed, disease free), 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.32[0.24; 7.21]-10 -NAVideman (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2016 10.510.01.0